- Home
- BHRB vs GHRS Comparison
BHRB vs GHRS Comparison
Compare BHRB & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHRB | GHRS |
|---|---|---|
| Founded | 1852 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.8M | 947.2M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BHRB | GHRS |
|---|---|---|
| Price | $61.65 | $21.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $71.80 | $41.38 |
| AVG Volume (30 Days) | 114.5K | ★ 255.2K |
| Earning Date | 04-23-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 173.76 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.62 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | $34.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.45 | $10.67 |
| 52 Week High | $70.90 | $24.66 |
Technical Indicators
Market Signals| Indicator | BHRB | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 60.68 |
| Support Level | $61.19 | $12.41 |
| Resistance Level | $62.85 | $22.88 |
| Average True Range (ATR) | 1.33 | 1.33 |
| MACD | -0.26 | -0.07 |
| Stochastic Oscillator | 14.48 | 67.96 |
Price Performance
Historical ComparisonAbout BHRB Burke & Herbert Financial Services Corp.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.